In addition, inhibition of the ERBB2 pathway with a neutralizing antibody or small-molecule inhibitor for ERBB2 normalizes CDKN1B expression, leading to cell cycle arrest in human breast cancer cells (Le et al., 2003). Here, CDKN1B is linked to breast carcinoma.